印度的胃癌治療市場:各治療類型，各類型，各類藥物，各給藥途徑，各流通管道，各地區，機會，預測，2019年～2033年

印度胃癌治療市場規模預計將從 2025 年的 3.787 億美元增長到 2033 年的 8.0589 億美元，預測期內（2026-2033 年）的複合年增長率為 9.90%。市場的成長歸因於印度胃腸道癌症盛行率的上升、普通民眾意識的增強以及對腫瘤學研究的投資增加。根據全球癌症觀察站估計，到2022年，胃癌將成為印度男性第五大常見癌症類型，佔所有癌症病例的6.2%。

延遲診斷是印度面臨的一大挑戰，通常是由於非特異性症狀以及該國農村地區診斷服務機會有限。因此，患者往往會罹患晚期癌症並需要更密集的治療。然而，公共衛生運動的加強和先進診斷技術的普及有助於提高該國的早期發現率。此外，印度的醫療保健基礎設施加上 "Ayushman Bharat" 等政府支持舉措，進一步增加了癌症治療的機會。另一方面，藥物開發技術的進步、生物相似藥的推出以及私人醫院和製藥公司之間日益增長的合作關係預計將為市場提供豐厚的成長機會。

本報告提供印度的胃癌治療市場相關調查，提供市場概要，以及各治療類型，各類藥物，各給藥途徑，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 印度的胃癌治療市場預測，2019年～2033年

• 市場規模分析與預測
• 市場佔有率分析與預測
  • 各治療類型
    • 免疫療法
    • 標靶治療
    • 化療
    • 其他
  • 各類型
    • 腺癌症
    • 胃腸道基質腫瘤(GIST)
    • 胃食道結點癌症
  • 各類藥物
    • PD-1/PD-L1抑制劑
    • HER2拮抗劑
    • VEGFR2拮抗劑
    • 其他
  • 給藥途徑
    • 口服
    • 注射
  • 各流通管道
    • 醫院藥局
    • 專門藥局及零售藥局
    • 其他
  • 各地區
    • 北部
    • 東部
    • 西部和中央部
    • 南部
  • 各企業市場佔有率分析(前五名公司以及其他- 以金額為準，2025年)
• 2025年的市場地圖分析

第6章 需求供給分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

• 市場促進因素
• 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

• 法規當局的認證
• 臨床試驗

第14章 專利的形勢

第15章 案例研究

第16章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • Novartis Healthcare Private Limited
  • Pfizer Limited
  • Mylan Pharmaceuticals Private Limited (Subsidiary of Viatris Inc.)
  • Merck & Co., Inc.
  • Roche Products (India) Private Limited
  • Teva India Private Limited
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Bristol Myers Squibb India Pvt Ltd
  • Samsung Bioepis Co., Ltd.
  • Celltrion Healthcare India Private Limited

第17章 策略性建議

第18章 關於調查公司·免責聲明

India stomach cancer treatment market is projected to witness a CAGR of 9.90% during the forecast period FY2026-FY2033, growing from USD 378.70 million in FY2025 to USD 805.89 million in FY2033. The market's growth can be attributed to the growing prevalence of gastrointestinal cancer, rising awareness among the general population, and increasing investments in oncology research in India. According to the estimates of the Global Cancer Observatory, in 2022, stomach cancer was the fifth most common type of cancer in men in India, accounting for 6.2% of all cancer cases.

In India, delayed diagnosis is a significant challenge, often caused due to non-specific symptoms and limited access to diagnostic services in rural areas in the country. This frequently results in patients presenting with advanced stages of cancer, requiring more intensive treatments. However, rising public health campaigns and access to advanced diagnostic technologies are helping increase early detection rates in the country. Additionally, India's expanding healthcare infrastructure, combined with government-backed initiatives such as Ayushman Bharat, is further increasing the accessibility of cancer care. Meanwhile, innovations in drug development, introduction of biosimilars, and increasing partnerships between private hospitals and pharmaceutical companies are further expected to provide lucrative growth opportunities for the market.

Rising Investments by Leading Hospitals Towards Cancer Care Boosts Market Growth

Hospitals across the country are allocating more resources for acquiring advanced diagnostic tools and technologies, utilizing cutting-edge treatment modalities, including immunotherapy and targeted therapy, and upgrading the oncology infrastructure. Such investments are enhancing the capacity of hospitals to provide comprehensive treatment, accurate diagnosis, and early detection, resulting in higher survival rates and improved patient outcomes. Hospital investments also foster clinical research, support the adoption of globally recognized practices, and facilitate participation in clinical trials, further supporting the market's expansion in the country.

For instance, in February 2025, Manipal Hospital, Baner, launched a preventive oncology clinic in order to empower the patient population with risk assessment, timely screening, and lifestyle counseling for improving treatment outcomes and performing a risk assessment to detect cancer at an early stage.

Introduction of Innovative Treatments and Public Health Policies Support Market Expansion

Rising efforts to bolster the availability of innovative therapies to combat stomach cancer in India in combination with the growing efforts of the government to increase the accessibility and affordability of various treatment solutions is one of the major drivers of the India stomach cancer treatment market. The introduction of immunotherapy drugs such as nivolumab and pembrolizumab for gastric cancer, which have shown improved survival rates, is reshaping treatment protocols.

Meanwhile, programs such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), which aims to integrate cancer screening into primary healthcare services, especially in underserved rural areas, further supporting the market's expansion. Moreover, initiatives such as the Pradhan Mantri Jan Arogya Yojana (PMJAY) are expanding access to cancer treatment by covering hospital expenses under government health insurance schemes, encouraging more patients to undergo treatment for stomach cancer, thereby increasing the market's demand.

Evolving Lifestyle is Driving the Market's Demand

The evolving lifestyle and eating habits in the country are one of the major drivers of the Indian stomach cancer treatment market. Habits such as increased consumption of processed foods, sedentary habits, rising obesity, chronic stress, and high salt intake are contributing to the high incidences of stomach cancer in India. Increasing preference for ordering junk food due to the associated convenience and preference for food products that have less fiber, high salt, and sugar, and are processed are also boosting the number of cases of stomach cancer in India. The gross order value for Zomato increased to USD 3.08 billion in FY2023 from USD 152.68 million in FY2018. The recognition of lifestyle's role in cancer risk is prompting public health initiatives and patient education, further increasing early diagnosis and treatment uptake.

Hospital Pharmacies Holds Major Market Share

Hospital pharmacies account for a major share of the India stomach cancer treatment market because hospitals serve as primary centers for cancer diagnosis, treatment, and management. Many stomach cancer patients in India require inpatient care for chemotherapy, targeted therapy, and immunotherapy administration, which are often delivered under strict medical supervision in hospital settings. Hospital pharmacies ensure immediate and reliable access to these essential oncology drugs, facilitating timely treatment and better patient outcomes. Additionally, leading hospital pharmacies across the country are focusing on mergers and acquisitions to expand their presence in the country and strengthen their position in the market. For instance, in March 2025, Apollo Healthco Limited, which operated the online platform Apollo 24/7 and the Apollo pharmacy chain, announced that it is planning on establishing 80-100 new outlets over the next two years across Bengal.

Impact of the U.S. Tariff on India Stomach Cancer Treatment Market

In April 2025, the government of the United States announced tariffs of 26% on Indian imports. However, pharmaceuticals were exempted from these tariffs. The decision highlights the importance placed on the role of generic and economically efficient life-saving medications in ensuring public health, national security, and economic stability. Exemption allows leading pharmaceutical companies to strengthen their presence in the industry, ensure the supply of essential medications, and focus on strategic partnerships, reinforcing their status in regional and global markets. They also ensure that the market players are able to provide affordable therapies for cancer both domestically and internationally.

Key Players Landscape and Outlook

The key players in the market are actively focusing on expanding their operations in India by investing in manufacturing and research and development sites across the country. For instance, Novartis AG invests approximately USD 400 million in its operations in India every year. This investment allows the company to focus on clinical trial operations and basic research and support the accelerated development and improved accessibility of innovative therapeutic solutions, such as immunotherapies and targeted treatments, to combat the growing threat of stomach cancer in India. Such investments by the key players of the market in the country's healthcare ecosystem are augmenting the growth of the market by ensuring the availability of advanced treatment solutions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. India Stomach Cancer Treatment Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Immunotherapy
    • 5.2.1.2. Targeted Therapy
      • 5.2.1.2.1. Biologics
      • 5.2.1.2.2. Biosimilar
    • 5.2.1.3. Chemotherapy
      • 5.2.1.3.1. Capecitabine
      • 5.2.1.3.2. Cisplatin
      • 5.2.1.3.3. Fluorouracil (5-FU)
      • 5.2.1.3.4. Oxaliplatin
      • 5.2.1.3.5. Others
    • 5.2.1.4. Others
  • 5.2.2. By Type
    • 5.2.2.1. Adenocarcinomas
    • 5.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
    • 5.2.2.3. Gastroesophageal Junction Cancer
  • 5.2.3. By Drug Class
    • 5.2.3.1. PD-1/PD-L1 Inhibitors
    • 5.2.3.2. HER2 Antagonists
    • 5.2.3.3. VEGFR2 Antagonists
    • 5.2.3.4. Other Drug Classes
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Injectable
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Specialty and Retail Pharmacies
    • 5.2.5.3. Others
  • 5.2.6. By Region
    • 5.2.6.1. North
    • 5.2.6.2. East
    • 5.2.6.3. West and Central
    • 5.2.6.4. South
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Treatment Type
  • 5.3.2. By Type
  • 5.3.3. By Drug Class
  • 5.3.4. By Route of Administration
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Healthcare Private Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Pfizer Limited
  • 16.3.3. Mylan Pharmaceuticals Private Limited (Subsidiary of Viatris Inc.)
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. Roche Products (India) Private Limited
  • 16.3.6. Teva India Private Limited
  • 16.3.7. Eli Lilly and Company (India) Pvt. Ltd.
  • 16.3.8. Bristol Myers Squibb India Pvt Ltd
  • 16.3.9. Samsung Bioepis Co., Ltd.
  • 16.3.10. Celltrion Healthcare India Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Stomach Cancer Treatment Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Stomach Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 3. India Stomach Cancer Treatment Market Share (%), By Type, FY2019-FY2033F
• Figure 4. India Stomach Cancer Treatment Market Share (%), By Drug Class, FY2019-FY2033F
• Figure 5. India Stomach Cancer Treatment Market Share (%), By Route of Administration, FY2019-FY2033F
• Figure 6. India Stomach Cancer Treatment Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 7. India Stomach Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 8. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Drug Class Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 12. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 13. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025